IUMPA–2: release of medroxyprogesterone acetate from the intrauterine system in the treatment of endometrial hyperplasia relative to the patient's body mass index (BMI)

Abstract

Aim

First, to develop a system of an intrauterine diaphragm with medroxyprogesterone acetate in the treatment of endometrial hyperplasia. Second, to check the distribution of this drug depending on the patient's BMI.

Materials and methods

The study comprised a group of 20 postmenopausal patients with histologically diagnosed simple hyperplasia treated with IUMPA-2 using endoscopic techniques (hysteroscopic targeted endometrial biopsy), histological methods (bioptate assessment) and ultrasound techniques (treatment volume and endometrial measurements).

Results

In all patients investigated the rate of medroxyprogesterone acetate release increased with BMI, which had an effect on the treatment time ranging between 35 and 14 days, respectively.

Conclusions

1) The BMI affects the rate of medroxyprogesterone acetate release from IUMPA-2. 2) In patients with a high BMI double (sequentially) application of a diaphragm should be considered.